US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
TG Therapeutics, Inc. - Common Stock
(NQ:
TGTX
)
54.29
+0.67 (+1.25%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about TG Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
TG Therapeutics (NASDAQ:TGTX) Combines Strong Growth With a Tight Technical Breakout Setup
↗
September 21, 2026
Via
Chartmill
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share
↗
September 18, 2026
TG Therapeutics (NASDAQ:TGTX) Chairman, President and Chief Executive Officer Mike Weiss said the company’s multiple sclerosis therapy, BRIUMVI, has captured more than one-third of the intravenous...
Via
MarketBeat
TG Therapeutics (NASDAQ:TGTX): A Fitting Candidate for Affordable Growth
↗
August 31, 2026
Via
Chartmill
TG Therapeutics (NASDAQ:TGTX) Combines Strong Growth with a Breakout Setup
↗
August 19, 2026
Via
Chartmill
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
↗
August 17, 2026
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences...
Via
MarketBeat
TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript
↗
August 10, 2026
BRIUMVI revenue surged 64% year-over-year as patient starts hit record levels.
Via
The Motley Fool
Topics
Earnings
TG Therapeutics (NASDAQ:TGTX) Falls as Q2 Revenue Beats but EPS Misses, Guidance Raised Below Estimates
↗
August 03, 2026
Via
Chartmill
TG Therapeutics (NASDAQ:TGTX) Meets Minervini's Trend Template with Accelerating Growth
↗
July 29, 2026
Via
Chartmill
TG Therapeutics Q2 Earnings Call Highlights
↗
August 03, 2026
TG Therapeutics (NASDAQ:TGTX) reported second-quarter 2026 revenue of $240 million and raised its full-year sales outlook for BRIUMVI, its treatment for relapsing multiple sclerosis, as the company...
Via
MarketBeat
Topics
Earnings
2 Fast-Growing Pharmaceutical Stocks to Buy Now
↗
July 08, 2026
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.
Via
The Motley Fool
TG THERAPEUTICS INC (NASDAQ:TGTX): High-Growth Momentum Meets Minervini Trend Template Technical Strength
↗
July 02, 2026
Via
Chartmill
TG Therapeutics Stock Surges After Drug Trial Update
↗
June 03, 2026
Shares of TG Therapeutics Inc (NASDAQ: TGTX) are climbing Wednesday after early-stage clinical trial data for new BRIUMVI MS formulation.
Via
Benzinga
TG THERAPEUTICS INC (NASDAQ:TGTX) Screens as Affordable Growth Play with Strong Revenue Surge and Discounted Valuation
↗
May 09, 2026
Via
Chartmill
TG Therapeutics (NASDAQ:TGTX) Q1 2026 Earnings Beat Revenue Guidance but Miss EPS Estimates
↗
May 06, 2026
Via
Chartmill
Topics
Earnings
TG Therapeutics Inc (NASDAQ:TGTX) Shows Strong Growth and Technical Setup for Potential Upside
↗
April 20, 2026
Via
Chartmill
TG Therapeutics Inc (NASDAQ:TGTX): An Affordable Growth Stock with Strong Momentum
↗
April 04, 2026
Via
Chartmill
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
↗
May 30, 2026
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.
Via
The Motley Fool
Topics
Regulatory Compliance
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position
↗
May 10, 2026
This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs.
Via
The Motley Fool
Topics
Regulatory Compliance
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
↗
May 10, 2026
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
Via
The Motley Fool
TG Therapeutics Inc (NASDAQ:TGTX) Presents a Compelling Momentum Case with Strong Growth and Technical Setup
↗
March 14, 2026
Via
Chartmill
TG THERAPEUTICS INC (NASDAQ:TGTX) Q4 2025 Earnings Miss Estimates Despite Strong BRIUMVI Outlook
↗
February 26, 2026
Via
Chartmill
Topics
Earnings
TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally
↗
January 15, 2026
Via
Stocktwits
TG Therapeutics (TGTX) Q1 2026 Earnings Transcript
↗
May 06, 2026
TG Therapeutics (TGTX) Q1 2026 Earnings Transcript
Via
The Motley Fool
TGTX Q1 2025 Earnings Call Transcript
↗
May 06, 2026
TGTX Q1 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment
↗
March 16, 2026
Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop
↗
March 16, 2026
This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.
Via
The Motley Fool
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript
↗
February 26, 2026
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript
Via
The Motley Fool
Soleus Adds a Significant Number of Celcuity Shares
↗
February 13, 2026
This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.
Via
The Motley Fool
TG Therapeutics Lights Up Super Bowl With Christina Applegate MS Campaign — Retail Sees 'Huge Win'
↗
February 09, 2026
TG Therapeutics reported that six-year data showed nearly 90% of patients on continuous Briumvi remained free of disability progression.
Via
Stocktwits
Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares
↗
February 02, 2026
This commercial-stage biotech develops therapies for B-cell malignancies and autoimmune diseases, leveraging a diverse clinical pipeline.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
